Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Anyone know what's gone wrong with the trade details, Its likeiton a few boards
John McDermott will be presenting the
@PALOH_Study
at the virtual ESHG conference on Tuesday 31st August. The first use of a pharmacogenetic test in a neonatal intensive care setting using the #genedrive AIHL test for MT-RNR1. Follow the link
https://t.co/4tP0DZEqa2?amp=1
Learn About Tiziana Life Sciences (NASDAQ: TLSA) in Exclusive Zoom Group Investor Call
Tuesday, August 10 at 4:15 pm ET
Add to your Calendar
Join Kunwar Shailubhai, CEO of Tiziana Life Sciences (NASDAQ: TLSA), to learn about the company’s targeted therapeutics being developed to transform treatment of liver diseases, inflammatory diseases, and cancer using proprietary oral, nasal, and inhaled formulation technologies.
Event information:
When: Aug 10, 2021 4:15 PM Eastern Time (US and Canada)
Topic: RedChip TLSA Zoom Event
Please click the link below to join the webinar:
us06web.zoom.us/j/84884583902
Meeting ID: 848 8458 3902
Dial by your location
US:
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)
Canada:
+1 647 558 0588 or +1 778 907 2071
United Kingdom:
+44 131 460 1196 or +44 203 481 5237 or +44 203 481 5240
Find your local number: zoom.us/u/kdthYPvXzZ
If you have any questions, or would like to learn more, contact me, Craig Brelsford, at (407) 571-0902, or by email at Craig@RedChip.com
About Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life Sciences is a dual-listed clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
Key Highlights:
• Transformational platform technologies
• Phase 2 oral immunotherapy study for Crohn’s Disease (CD)
• Reporting top-line data from COVID-19 trial in Jan. 2021
• Strong intellectual property protections
• Proven leadership team with ‘bench to market’ experience
• FDA approved expanded access use for Foralumab treating a Secondary Progressive Multiple Sclerosis patient
• Successfully spun off StemPrintER business in Q4 2020
View Investor Deck
Investor Contact:
www.tlsainfo.com/
www.tizianalifesciences.com/
Disclosure:
RedChip Companies, Inc. research reports, company profil
https ://investorplace.com/2021/03/7-penny-stocks-to-buy-with-robinhood-play-moneys
On the TLSA website
BG
https://twitter.com/Alexios1201/status/1346396711380545539?s=19
Hi Badger99,
Thanks for your prompt reply.
BG
Hi just registered today as I have a question that someone on this board might help me with.I invest with a major bank starting with an H. When I tried to buy RBD shares A message comes up saying. We no longer allow investment in this stock. Can anyone give a reason for this.
BG